Adoptive cell transfer-based therapies have received lots of attention in the past five years for treating various types of cancers. <i>Kymriah</i>, a chimeric antigen receptor T-cell (CAR-T) therapy that was approved recently as the first cell-based gene therapy in the United States, is a preeminent example. Alternatively, tumor infiltrating lymphocytes (TILs) can be harvested from patients, expanded ex vivo, and re-administered back into the same patient to trigger tumor suppression. However, the tumor microenvironment has evolved numerous strategies to downregulate the cytotoxicity of the transferred T cells. In this talk, I will describe new strategies that are based on chemoenzymatic editing of cell-surface glycans to boost the efficacy of cell-based immunotherapy. <br/>

Boosting the efficacy of cell-based immunotherapy via cell-surface glycan editing

Macromolecular Chemistry: The Second Century

[Author Benefits](https://scimeetings.acs.org/?utm_source=pubs_content_marketing&utm_medium=website&utm_campaign=0320_MCF_NPI_Launch_Spring_Homepage&ref=pubs_content_marketing)

[How to use SciMeetings](https://storage.googleapis.com/dl.morressier.com/acs/SciMeetings-ACSSpring2020-HowToGuide_M3020-Final.pdf)

[Frequently Asked Questions](https://storage.googleapis.com/dl.morressier.com/acs/SciMtng_ACSNMSp2020_FAQ_M3120_Final.pdf)

ACS Spring 2020 National Meeting & Expo

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.